With leadership from Canada’s Drug Agency (CDA-AMC), the Pan-Canadian Cancer Genomics Community of Practice is prioritizing, as a first collaborative activity, the development of a consensus-based assessment framework to guide adoption and funding decisions for genetic and genomic biomarkers in cancer care. By identifying best practices and gaps across different jurisdictions, the Community of Practice will help define actionable recommendations to facilitate implementation of the framework and help ensure timely and equitable access to testing. This work is currently underway.